Gary Fischer
Analyst · Craig-Hallum
Thank you, Leslie, and good afternoon, everyone. Total revenue for the fourth quarter of 2020 was $27 million, up 6% from $25.5 million in the third quarter of 2020, and up more than 46% from $18.4 million in the fourth quarter of 2019. Of our total revenue, substrate sales were $21.5 million in Q4, compared with $20.3 million in the third quarter, and $14.5 million in Q4 of 2019. Revenue from our raw material joint ventures was $5.5 million in Q4, up from $5.2 million in Q3, and up from $3.9 million in Q4. In the fourth quarter of 2020, revenue from Asia Pacific was 71%, Europe was 16% and Taiwan was 13%, and North America was 13%. So, actually, Taiwan [indiscernible]. In the fourth quarter, 2 customers reached 10% of revenue, and the top 5 customers generated approximately 37% of total revenue. Gross margin in the fourth quarter was 33.9%, down slightly from 34.6% in the prior quarter. Given that, in Q4 of 2019, the gross margin was 21%, the year-on-year comparison is very encouraging. This spread is a quick illustration of the leverage we get from higher revenue, and I think it is noteworthy in terms of evaluating our business model. Both Q3 of 2020 and the recent Q4 are much stronger. I think we can still achieve higher than the recent 2 quarters in terms of gross margin, and Morris and I will be watching for some specific items. One, of course, is product mix, another is overall revenue volume. A third is that we think there are still some gains to be made in yields in manufacturing efficiencies, as the manufacturing teams settle into the new locations. Total operating expenses in Q4 were $7.2 million, up from $6.6 million in the prior quarter, and $6.7 million in Q4 of 2019. R&D is up $125,000 over Q3, as we are making good progress on some R&D programs. SG&A is up $460,000, and that increase is driven by several factors. The largest contributor is year-end bonuses totaling about $350,000. About half of this was in the 2 consolidated raw material companies. We had a good year with a strong finish, and in Q4, it was nice to be able to reward our team. Second, we had a charge for bad debt of $50,000, something that does not happen too often in our business model. We also had charges related to the private equity round and preparing for the IPO in China, and travel was up as a number of us, including Morrison and me, went to China. Total stock compensation expense for the fourth quarter was $692,000. Operating profit for the fourth quarter was $1.9 million, compared with an operating profit of $2.2 million in the previous quarter, and an operating loss of $2.8 million in Q4 of 2019. Other income net for the fourth quarter 2020 was a gain of almost $600,000. This includes grants of almost $540,000. Especially noteworthy is a net profit of $354,000 from the partially owned companies in the AXT supply chain, accounted for under the equity method, so that's good news. It's nice to see that group be positive again. The market for raw materials has tightened up, and this is a good sign. We think this will hold in 2021. These gains were offset by a foreign exchange loss of $300,000 and a net charge of $40,000 for interest income and expense. Income tax for the fourth quarter of 2020 was a charge of $108,000 compared with a charge of 673,000 in Q3. Our Q4 results included approximately $400,000 in tariffs as a result of the 25% tariff charged on importing wafers into the United States from China. For Q4 2020, we have a net profit of $2.1 million, or profit of $0.05 per diluted share. By comparison, we had a net profit of $1 million, or profit $0.02 per diluted share in the third quarter of 2020, and a net loss of $2 million, or a loss of $0.05 per share in Q4 of 2019. The share count for Q4 was 42.042 million shares. Cash, cash equivalents and investments were $78.6 million as of December 31. By comparison, at September 30, it was $29.8 million. This increase is a result of the $48.8 million -- pardon me. This increase of $48.8 million is directly related to the IPO [percepts] of partnering with private equity firms in China. Without that, cash would have been flat. I'll give a brief update on the Star Market IPO project in a moment. Depreciation and amortization in the fourth quarter was $1.37 million, and investments were $5.3 million. Net inventory at December 31 increased by $3.2 million in the quarter and ended at $51.5 million. Ending inventory consisted of approximately 48% in raw materials, 47% for work in progress, and only 5% in finished goods. The largest increase was in raw materials, and this was deliberate on our part. Okay. This concludes the discussion of our quarterly financials. Let me just briefly highlight the fiscal year. For the fiscal year 2020, revenue was $95.4 million, up almost 15% from $83.3 million in fiscal year 2019. This represented growth in every revenue category across our portfolio and underscores the momentum we are seeing in major technology trends that drive demand for our compound semiconductor substrates. Gross margin for fiscal year 2020 was 31.7% of revenues, up from 29.8% of revenue for fiscal year 2019. Net income for the fiscal year 2020 was $3.2 million or $0.07 per diluted share, compared with a net loss of $2.6 million, or $0.07 per share, for fiscal year 2019. I'd now like to give you a brief update and comments about our plan to list our company in China on the STAR Market in Shanghai, and these comments also include some forward-looking statements. On November 16, we announced a strategic plan to access China's capital markets and progress to an initial public offering and -- by our company, the formal name of Beijing Tongmei [Xtal] Technology Company, our wafer manufacturing company there in China, although the short name is Tongmei. The first major step in this process is engaging reputable private equity firms in China to invest funds in Tongmei. This went smoothly, was met with enthusiasm, and closed faster than we expected. In January, the final installment of $1.5 million in private equity funding came in. In total, we have banked approximately $49 million, and in aggregate, sold approximately 7.28% of Tongmei. Simultaneously, we have been working on some reorganization plans, which will make Tongmei have broader product lines, more consolidated revenue, more customers and, in general, strengthen this company and support the high valuations awarded by that investment community. One example is that we are moving our 2 [indiscernible] raw material companies, BoYu and Jin Mei, into the Tongmei family. We did receive some very positive feedback from a number of shareholders when we announced this. Several of you described this as unlocking a hidden asset, and that resonates with Morris, Leslie, and me. Morris founded totally in 1998, and the management team has nurtured and steered that company now for over 22 years. Morris and I both spent over 2 months there in the fall of 2020, including the mandatory 2-week quarantine. Especially with the relocation having gone so well, we agree that we are now unlocking a hidden asset in China. One of you also responded with an e-mail that just said, "Wow,' and that resonates for us, too. We hope to file the application with the China Securities Regulatory Commission by the end of June. There's a lot to accomplish to achieve that goal, and it will be a busy 4 months for us. Okay. This concludes the financial review. I'll now turn the call over to Dr. Dr. Morris Young for a review of our business. Morris?